M3V Stock Overview
Develops, markets, and sells software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
MeVis Medical Solutions AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €24.00 |
| 52 Week High | €26.40 |
| 52 Week Low | €22.40 |
| Beta | 0.0019 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -8.40% |
| 33 Year Change | -23.57% |
| 5 Year Change | -19.46% |
| Change since IPO | -52.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| M3V | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | -0.02% |
| 1Y | -8.4% | -32.5% | 8.2% |
Return vs Industry: M3V exceeded the German Healthcare Services industry which returned -32.5% over the past year.
Return vs Market: M3V underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| M3V volatility | |
|---|---|
| M3V Average Weekly Movement | 2.2% |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: M3V has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: M3V's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 116 | Marcus Kirchhoff | www.mevis.de |
MeVis Medical Solutions AG develops, markets, and sells software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, liver, and neurological diseases. It offers X-ray based radiography procedures, including computed tomography, mammography/digital tomosynthesis, magnetic resonance imaging, and digital sonography; and provides services in the field of software programming for medical technology companies, which comprise provision of software developers, product and project managers, application specialists, and test engineers.
MeVis Medical Solutions AG Fundamentals Summary
| M3V fundamental statistics | |
|---|---|
| Market cap | €45.14m |
| Earnings (TTM) | €5.75m |
| Revenue (TTM) | €17.64m |
7.8x
P/E Ratio2.6x
P/S RatioIs M3V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| M3V income statement (TTM) | |
|---|---|
| Revenue | €17.64m |
| Cost of Revenue | €10.72m |
| Gross Profit | €6.93m |
| Other Expenses | €1.18m |
| Earnings | €5.75m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | 3.16 |
| Gross Margin | 39.27% |
| Net Profit Margin | 32.60% |
| Debt/Equity Ratio | 0% |
How did M3V perform over the long term?
See historical performance and comparison